Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02774343 · ClinicalTrials.gov registry record · Phase 1
PPARγ Agonist Treatment for Cocaine Dependence
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02774343 is a Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 30 participants.
The verdict
NCT02774343, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether a medication called pioglitazone (trade name Actos) can reduce behavioral problems associated with cocaine use, improve brain structural changes associated with cocaine use and reduce cocaine craving and drug use in cocaine dependent patients.
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- BEHAVIORAL Contingency Management
- BEHAVIORAL Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02774343
The ClinicalTrials.gov registry entry for NCT02774343 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02774343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02774343 about?
NCT02774343 is a clinical study titled "PPARγ Agonist Treatment for Cocaine Dependence". The purpose of this research study is to determine whether a medication called pioglitazone (trade name Actos) can reduce behavioral problems associated with cocaine use, improve brain structural changes associated with cocaine use and reduce cocaine craving and drug use in cocaine dependent patient...
What is the current status of trial NCT02774343?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-08. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02774343?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), Contingency Management (BEHAVIORAL), Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT02774343?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.